Uppsala, Sweden 2019-02-12 OssDsign AB, the Swedish designer, manufacturer and distributor of regenerative implants for improved healing of bone defects, today announced the closing of a private placement of 64 MSEK (6 MEUR). The financing was achieved through a combination of Swedish private investors and the French investment management company Alto Invest. OssDsign will now also initiate the process towards a stock exchange listing during 2019.
Erik Penser Bank acted as financial advisor for the private placement and will continue to work with OssDsign also in the next phase as the company begins the process towards a listing on Nasdaq First North during 2019.
Anders Lundqvist, CEO of OssDsign, said: “With the private placement secured and the process for listing initiated we can now plan for further investments in our sales expansion efforts of OssDsign’s regenerative implant solutions for improved healing of bone defects. Focus will be on accelerating ongoing commercial activities in the US followed by key markets in Europe. The proceeds will also be used for entering new markets, primarily preparing for market introduction in Japan. We have, in parallel to the regulatory process, initiated pre-marketing activities. With ethical committee approval already in place, leading surgeons in Japan have started to build experience with the OssDsign technology prior to regulatory approval and launch. This initiative will give us the opportunity to present follow-up results of Japanese patients in time for launch. The funding is therefore an important step towards becoming a strong global provider of a complete regenerative cranial and facial reconstruction solution, which is our current commercial focus.”
For further information, please contact:
Anders Lundqvist, CEO, OssDsign AB
Phone: +46 73 206 98 08, email: email@example.com
OssDsign is a Swedish medtech company dedicated to creating regenerative implants for improved healing of bone defects. OssDsign provides neurosurgeons and reconstructive plastic surgeons around the world with an expanding range of innovative implant solutions for improved patient outcomes. OssDsign’s technology is the result of collaboration between clinical researchers at the Karolinska University Hospital, Stockholm, and material science experts at the Ångström Laboratory at Uppsala University.